Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection | Zendy

Andrew I. Flyak | Zendy; Xiaoli Shen | Zendy; Charles D. Murin | Zendy; Hannah L. Turner | Zendy; Joshua A. David | Zendy; Marnie L. Fusco | Zendy; Rebecca Lampley | Zendy; Nurgun Kose | Zendy; Philipp A. Ilinykh | Zendy; Natalia A. Kuzmina | Zendy; Andre Branchizio | Zendy; Hannah A. D. King | Zendy; Leland Brown | Zendy; Christopher Bryan | Zendy; Edgar Davidson | Zendy; Benjamin J. Doranz | Zendy; James C. Slaughter | Zendy; Gopal Sapparapu | Zendy; Curtis Klages | Zendy; Thomas G. Ksiazek | Zendy; Erica Ollmann Saphire | Zendy; Andrew B. Ward | Zendy; Alexander Bukreyev | Zendy; James E. Crowe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection

Author(s) -

Andrew I. Flyak,

Xiaoli Shen,

Charles D. Murin,

Hannah L. Turner,

Joshua A. David,

Marnie L. Fusco,

Rebecca Lampley,

Nurgun Kose,

Philipp A. Ilinykh,

Natalia A. Kuzmina,

Andre Branchizio,

Hannah A. D. King,

Leland Brown,

Christopher Bryan,

Edgar Davidson,

Benjamin J. Doranz,

James C. Slaughter,

Gopal Sapparapu,

Curtis Klages,

Thomas G. Ksiazek,

Erica Ollmann Saphire,

Andrew B. Ward,

Alexander Bukreyev,

James E. Crowe

Publication year - 2016

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2015.12.022

Subject(s) - ebola virus , ebolavirus , virology , biology , epitope , monoclonal antibody , antibody , heterologous , glycan , virus , glycoprotein , antigen , neutralization , immunology , microbiology and biotechnology , gene , genetics

Recent studies have suggested that antibody-mediated protection against the Ebolaviruses may be achievable, but little is known about whether or not antibodies can confer cross-reactive protection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan virus (SUDV), and Bundibugyo virus (BDBV). We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda. We determined that a large proportion of mAbs with potent neutralizing activity against BDBV bind to the glycan cap and recognize diverse epitopes within this major antigenic site. We identified several glycan cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb that completely protected guinea pigs from the lethal challenge with heterologous EBOV. Our results provide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research